Loading…
Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications
Extracellular ATP (ATPo) and adenosine are cytotoxic to several cancer cell lines, suggesting their potential use for anticancer therapy. Adenosine causes cytotoxicity, either when added exogenously or when generated from ATPo hydrolysis, via mechanisms which are not mutually exclusive and which inv...
Saved in:
Published in: | BioFactors (Oxford) 2006, Vol.27 (1-4), p.213-230 |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3 |
---|---|
cites | cdi_FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3 |
container_end_page | 230 |
container_issue | 1-4 |
container_start_page | 213 |
container_title | BioFactors (Oxford) |
container_volume | 27 |
creator | Seetulsingh-Goorah, Sharmila P. |
description | Extracellular ATP (ATPo) and adenosine are cytotoxic to several cancer cell lines, suggesting their potential use for anticancer therapy. Adenosine causes cytotoxicity, either when added exogenously or when generated from ATPo hydrolysis, via mechanisms which are not mutually exclusive and which involve, adenosine receptor activation, pyrimidine starvation and/or increases in intracellular S‐adenosylhomocysteine: S‐adenosylmethionine ratio. Given that adenosine also appears to protect against cytotoxicity via mechanisms including immunity against damage by oxygen free radicals, an understanding of the contribution of adenosine to ATPo‐induced cytotoxicity is thus crucial, when considering any potential therapeutic use for these compounds. However, such an understanding has been largely hindered by the fact that many studies have not focused enough on the possibility that both ATPo and adenosine may mediate cytotoxicity in the same system. Such studies can benefit from use a range of ATPo concentrations when assessing the contribution of adenosine to ATPo‐induced cytotoxicity. Whilst future molecular and pharmacological studies are needed to establish the nature of the cytotoxic adenosine receptor, it is possible that more than just one adenosine receptor type is involved and that the cytotoxic receptor(s) type is more likely to have a low affinity for adenosine. Activation of the adenosine receptor(s) would thus lead to cytotoxicity only at relatively high adenosine concentrations, while lower adenosine concentrations mediate non‐cytotoxic physiological effects. |
doi_str_mv | 10.1002/biof.5520270119 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68909676</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68909676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7vpx9iY9eeuapE2T4ElFV8FPVAQPhiSdutG2WZsu2n9v110UT55mGJ73ZXgQ2iF4RDCm-8b5YsQYxZRjQuQKGhLBaSywIKtoiCUjcZYmyQBthPCKMUlwKtbRgPQ05ZwP0fMl2ImuXahC5ItI51D74GqIXZ3PLOSR7Vrf-k9nXdtFus6jdgKuiWzpamd1-X2aTrrgfOlfvi-umpb90jpfhy20VugywPZybqKH05P747P44np8fnx4EdtEMBnL_hlbpIaaNBWMGcYJtZbkGEhBCy2lzKgBKtMMDEjNZEoSbTC1eWa4AUg20d6id9r49xmEVlUuWChLXYOfBZUJiWXGsx7cX4C28SE0UKhp4yrddIpgNVeq5krVr9I-sbusnpkK8l9-6bAHDhbAhyuh-69PHZ1fn_6pjxdpF1r4_Enr5k1lPOFMPV6N1c2TELc393dKJF8xspTo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68909676</pqid></control><display><type>article</type><title>Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Seetulsingh-Goorah, Sharmila P.</creator><creatorcontrib>Seetulsingh-Goorah, Sharmila P.</creatorcontrib><description>Extracellular ATP (ATPo) and adenosine are cytotoxic to several cancer cell lines, suggesting their potential use for anticancer therapy. Adenosine causes cytotoxicity, either when added exogenously or when generated from ATPo hydrolysis, via mechanisms which are not mutually exclusive and which involve, adenosine receptor activation, pyrimidine starvation and/or increases in intracellular S‐adenosylhomocysteine: S‐adenosylmethionine ratio. Given that adenosine also appears to protect against cytotoxicity via mechanisms including immunity against damage by oxygen free radicals, an understanding of the contribution of adenosine to ATPo‐induced cytotoxicity is thus crucial, when considering any potential therapeutic use for these compounds. However, such an understanding has been largely hindered by the fact that many studies have not focused enough on the possibility that both ATPo and adenosine may mediate cytotoxicity in the same system. Such studies can benefit from use a range of ATPo concentrations when assessing the contribution of adenosine to ATPo‐induced cytotoxicity. Whilst future molecular and pharmacological studies are needed to establish the nature of the cytotoxic adenosine receptor, it is possible that more than just one adenosine receptor type is involved and that the cytotoxic receptor(s) type is more likely to have a low affinity for adenosine. Activation of the adenosine receptor(s) would thus lead to cytotoxicity only at relatively high adenosine concentrations, while lower adenosine concentrations mediate non‐cytotoxic physiological effects.</description><identifier>ISSN: 0951-6433</identifier><identifier>EISSN: 1872-8081</identifier><identifier>DOI: 10.1002/biof.5520270119</identifier><identifier>PMID: 17012777</identifier><language>eng</language><publisher>Amsterdam: IOS Press</publisher><subject>Adenosine ; Adenosine - metabolism ; Adenosine - pharmacology ; Adenosine Triphosphate - metabolism ; Adenosine Triphosphate - pharmacology ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Apoptosis - physiology ; Cell Survival - drug effects ; Cell Survival - physiology ; clinical uses ; cytotoxicity ; extracellular ATP (ATPo) ; Humans ; Models, Biological ; P1 receptors ; P2 receptors ; pyrimidine starvation ; Receptors, Purinergic - metabolism</subject><ispartof>BioFactors (Oxford), 2006, Vol.27 (1-4), p.213-230</ispartof><rights>Copyright © 2006 International Union of Biochemistry and Molecular Biology, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3</citedby><cites>FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17012777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seetulsingh-Goorah, Sharmila P.</creatorcontrib><title>Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications</title><title>BioFactors (Oxford)</title><addtitle>BioFactors</addtitle><description>Extracellular ATP (ATPo) and adenosine are cytotoxic to several cancer cell lines, suggesting their potential use for anticancer therapy. Adenosine causes cytotoxicity, either when added exogenously or when generated from ATPo hydrolysis, via mechanisms which are not mutually exclusive and which involve, adenosine receptor activation, pyrimidine starvation and/or increases in intracellular S‐adenosylhomocysteine: S‐adenosylmethionine ratio. Given that adenosine also appears to protect against cytotoxicity via mechanisms including immunity against damage by oxygen free radicals, an understanding of the contribution of adenosine to ATPo‐induced cytotoxicity is thus crucial, when considering any potential therapeutic use for these compounds. However, such an understanding has been largely hindered by the fact that many studies have not focused enough on the possibility that both ATPo and adenosine may mediate cytotoxicity in the same system. Such studies can benefit from use a range of ATPo concentrations when assessing the contribution of adenosine to ATPo‐induced cytotoxicity. Whilst future molecular and pharmacological studies are needed to establish the nature of the cytotoxic adenosine receptor, it is possible that more than just one adenosine receptor type is involved and that the cytotoxic receptor(s) type is more likely to have a low affinity for adenosine. Activation of the adenosine receptor(s) would thus lead to cytotoxicity only at relatively high adenosine concentrations, while lower adenosine concentrations mediate non‐cytotoxic physiological effects.</description><subject>Adenosine</subject><subject>Adenosine - metabolism</subject><subject>Adenosine - pharmacology</subject><subject>Adenosine Triphosphate - metabolism</subject><subject>Adenosine Triphosphate - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Cell Survival - drug effects</subject><subject>Cell Survival - physiology</subject><subject>clinical uses</subject><subject>cytotoxicity</subject><subject>extracellular ATP (ATPo)</subject><subject>Humans</subject><subject>Models, Biological</subject><subject>P1 receptors</subject><subject>P2 receptors</subject><subject>pyrimidine starvation</subject><subject>Receptors, Purinergic - metabolism</subject><issn>0951-6433</issn><issn>1872-8081</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkE1LxDAQhoMo7vpx9iY9eeuapE2T4ElFV8FPVAQPhiSdutG2WZsu2n9v110UT55mGJ73ZXgQ2iF4RDCm-8b5YsQYxZRjQuQKGhLBaSywIKtoiCUjcZYmyQBthPCKMUlwKtbRgPQ05ZwP0fMl2ImuXahC5ItI51D74GqIXZ3PLOSR7Vrf-k9nXdtFus6jdgKuiWzpamd1-X2aTrrgfOlfvi-umpb90jpfhy20VugywPZybqKH05P747P44np8fnx4EdtEMBnL_hlbpIaaNBWMGcYJtZbkGEhBCy2lzKgBKtMMDEjNZEoSbTC1eWa4AUg20d6id9r49xmEVlUuWChLXYOfBZUJiWXGsx7cX4C28SE0UKhp4yrddIpgNVeq5krVr9I-sbusnpkK8l9-6bAHDhbAhyuh-69PHZ1fn_6pjxdpF1r4_Enr5k1lPOFMPV6N1c2TELc393dKJF8xspTo</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Seetulsingh-Goorah, Sharmila P.</creator><general>IOS Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications</title><author>Seetulsingh-Goorah, Sharmila P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenosine</topic><topic>Adenosine - metabolism</topic><topic>Adenosine - pharmacology</topic><topic>Adenosine Triphosphate - metabolism</topic><topic>Adenosine Triphosphate - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Cell Survival - drug effects</topic><topic>Cell Survival - physiology</topic><topic>clinical uses</topic><topic>cytotoxicity</topic><topic>extracellular ATP (ATPo)</topic><topic>Humans</topic><topic>Models, Biological</topic><topic>P1 receptors</topic><topic>P2 receptors</topic><topic>pyrimidine starvation</topic><topic>Receptors, Purinergic - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seetulsingh-Goorah, Sharmila P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BioFactors (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seetulsingh-Goorah, Sharmila P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications</atitle><jtitle>BioFactors (Oxford)</jtitle><addtitle>BioFactors</addtitle><date>2006</date><risdate>2006</risdate><volume>27</volume><issue>1-4</issue><spage>213</spage><epage>230</epage><pages>213-230</pages><issn>0951-6433</issn><eissn>1872-8081</eissn><abstract>Extracellular ATP (ATPo) and adenosine are cytotoxic to several cancer cell lines, suggesting their potential use for anticancer therapy. Adenosine causes cytotoxicity, either when added exogenously or when generated from ATPo hydrolysis, via mechanisms which are not mutually exclusive and which involve, adenosine receptor activation, pyrimidine starvation and/or increases in intracellular S‐adenosylhomocysteine: S‐adenosylmethionine ratio. Given that adenosine also appears to protect against cytotoxicity via mechanisms including immunity against damage by oxygen free radicals, an understanding of the contribution of adenosine to ATPo‐induced cytotoxicity is thus crucial, when considering any potential therapeutic use for these compounds. However, such an understanding has been largely hindered by the fact that many studies have not focused enough on the possibility that both ATPo and adenosine may mediate cytotoxicity in the same system. Such studies can benefit from use a range of ATPo concentrations when assessing the contribution of adenosine to ATPo‐induced cytotoxicity. Whilst future molecular and pharmacological studies are needed to establish the nature of the cytotoxic adenosine receptor, it is possible that more than just one adenosine receptor type is involved and that the cytotoxic receptor(s) type is more likely to have a low affinity for adenosine. Activation of the adenosine receptor(s) would thus lead to cytotoxicity only at relatively high adenosine concentrations, while lower adenosine concentrations mediate non‐cytotoxic physiological effects.</abstract><cop>Amsterdam</cop><pub>IOS Press</pub><pmid>17012777</pmid><doi>10.1002/biof.5520270119</doi><tpages>18</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0951-6433 |
ispartof | BioFactors (Oxford), 2006, Vol.27 (1-4), p.213-230 |
issn | 0951-6433 1872-8081 |
language | eng |
recordid | cdi_proquest_miscellaneous_68909676 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adenosine Adenosine - metabolism Adenosine - pharmacology Adenosine Triphosphate - metabolism Adenosine Triphosphate - pharmacology Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Apoptosis - physiology Cell Survival - drug effects Cell Survival - physiology clinical uses cytotoxicity extracellular ATP (ATPo) Humans Models, Biological P1 receptors P2 receptors pyrimidine starvation Receptors, Purinergic - metabolism |
title | Mechanisms of adenosine-induced cytotoxicity and their clinical and physiological implications |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A44%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanisms%20of%20adenosine-induced%20cytotoxicity%20and%20their%20clinical%20and%20physiological%20implications&rft.jtitle=BioFactors%20(Oxford)&rft.au=Seetulsingh-Goorah,%20Sharmila%20P.&rft.date=2006&rft.volume=27&rft.issue=1-4&rft.spage=213&rft.epage=230&rft.pages=213-230&rft.issn=0951-6433&rft.eissn=1872-8081&rft_id=info:doi/10.1002/biof.5520270119&rft_dat=%3Cproquest_cross%3E68909676%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3859-9277cf4b2b44855b5712cc1d0e1f2fa99962be2946ebe9a59413ab02cd6b7bee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68909676&rft_id=info:pmid/17012777&rfr_iscdi=true |